DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2016–N–0969]

Authorization of Emergency Use of an In Vitro Diagnostic Device for Diagnosis of Zika Virus Infection; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) for an in vitro diagnostic device for the diagnosis of Zika virus infection in response to the Zika virus outbreak in the Americas. FDA issued this Authorization under the Federal Food, Drug, and Cosmetic Act (the FD&C Act), as requested by the U.S. Centers for Disease Control and Prevention (CDC). The Authorization contains, among other things, conditions on the emergency use of the authorized in vitro diagnostic device. The Authorization follows the February 26, 2016, determination by the Department of Health and Human Services (HHS) Secretary that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and that involves Zika virus. On the basis of such determination, the HHS Secretary declared on February 26, 2016, that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection subject to the terms of any authorization issued under the FD&C Act. The Authorization, which includes an explanation of the reasons for issuance, is reprinted in this document.

DATES: The Authorization is effective as of February 26, 2016.

ADDRESSES: Submit written requests for single copies of the EUA to the Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4338, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the Authorization may be sent. See the SUPPLEMENTARY INFORMATION section for electronic access to the Authorization.

FOR FURTHER INFORMATION CONTACT: Carmen Maher, Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4347, Silver Spring, MD 20993–0002, 301–796–8510.

SUPPLEMENTARY INFORMATION:

I. Background

Section 564 of the FD&C Act (21 U.S.C. 360bbb–3) as amended by the Project BioShield Act of 2004 (Pub. L. 108–276) and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113–5) allows FDA to strengthen the public health protections against biological, chemical, nuclear, and radiological agents. Among other things, section 564 of the FD&C Act allows FDA to authorize the use of an unapproved medical product or an unapproved use of an approved medical product in certain situations. With this EUA authority, FDA can help assure that medical countermeasures may be used in emergencies to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by biological, chemical, nuclear, or radiological agents; when there are no adequate, approved, and available alternatives.

Section 564(b)(1) of the FD&C Act provides that, before an EUA may be issued, the Secretary of HHS must declare that circumstances exist justifying the authorization based on one of the following grounds: (1) A determination by the Secretary of Homeland Security that there is a domestic emergency, or a significant potential for a domestic emergency, involving a heightened risk of attack with a biological, chemical, radiological, or nuclear agent or agents; (2) a determination by the Secretary of Defense that there is a military emergency, or a significant potential for a military emergency, involving a heightened risk to U.S. military forces of attack with a biological, chemical, radiological, or nuclear agent or agents; (3) a determination by the Secretary of HHS that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves a biological, chemical, radiological, or nuclear agent or agents, or a disease or condition that may be attributable to such agent or agents; or (4) the identification of a material threat by the Secretary of Homeland Security under section 319F–2 of the Public Health Service (PHS) Act (42 U.S.C. 247d–6b) sufficient to affect national security or the health and security of U.S. citizens living abroad.

Once the Secretary of HHS has declared that circumstances exist justifying an authorization under section 564 of the FD&C Act, FDA may authorize the emergency use of a drug, device, or biological product if the Agency concludes that the statutory criteria are satisfied. Under section 564(h)(1) of the FD&C Act, FDA is required to publish in the Federal Register a notice of each authorization, and such termination or revocation of an authorization, and an explanation of the reasons for the action. Section 564 of the FD&C Act permits FDA to authorize the introduction into interstate commerce of a drug, device, or biological product intended for use when the Secretary of HHS has declared that circumstances exist justifying the authorization of emergency use. Products appropriate for emergency use may include products and uses that are not approved, cleared, or licensed under sections 505, 510(k), or 515 of the FD&C Act (21 U.S.C. 355, 360(k), and 360e) or section 351 of the PHS Act (42 U.S.C. 262). FDA may issue an EUA only if, after consultation with the HHS Assistant Secretary for Preparedness and Response, the Director of the National Institutes of Health, and the Director of the CDC (to the extent feasible and appropriate given the applicable circumstances), FDA concludes: (1) That an agent referred to in a declaration of emergency or threat can cause a serious or life-threatening disease or condition; and (2) that, based on the totality of scientific evidence available to FDA, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that: (A) The product may be effective in diagnosing, treating, or preventing (i) such disease or condition; or (ii) a serious or life-threatening disease or condition caused by a product authorized under section 564, approved or cleared under the FD&C Act, or licensed under section 351 of the PHS Act, for diagnosing, treating, or preventing such a disease or condition caused by such an agent; and (B) the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified in a declaration under section 564(b)(1)(D) of the FD&C Act, if.

1 The Secretary of HHS has delegated the authority to issue an EUA under section 564 of the FD&C Act to the Commissioner of Food and Drugs.
applicable; (3) that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such disease or condition; and (4) that such other criteria as may be prescribed by regulation are satisfied.

No other criteria for issuance have been prescribed by regulation under section 564(c)(4) of the FD&C Act. Because the statute is self-executing, regulations or guidance are not required for FDA to implement the EUA authority.

II. EUA Request for an In Vitro Diagnostic Device for Diagnosis of Zika Virus Infection

On February 26, 2016, the Secretary of HHS determined that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and that involves Zika virus. On February 26, 2016, under section 564(b)(1) of the FD&C Act, and on the basis of such determination, the Secretary of HHS declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection, subject to the terms of any authorization issued under section 564 of the FD&C Act. Notice of the determination and declaration of the Secretary was published in the Federal Register on March 2, 2016 (81 FR 10878). On February 22, 2016, CDC requested, and on February 26, 2016, FDA issued, an EUA for the CDC Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC–ELISA), subject to the terms of the Authorization.

III. Electronic Access

An electronic version of this document and the full text of the Authorization are available on the Internet at http://www.regulations.gov.

IV. The Authorization

Having concluded that the criteria for issuance of the Authorization under section 564(c) of the FD&C Act are met, FDA has authorized the emergency use of an in vitro diagnostic device for diagnosis of Zika virus infection subject to the terms of the Authorization. The Authorization in its entirety (not including the authorized versions of the fact sheets and other written materials) follows and provides an explanation of the reasons for its issuance, as required by section 564(h)(1) of the FD&C Act:
February 26, 2016

Thomas R. Frieden, M.D., M.P.H.
Director
Centers for Disease Control and Prevention
1600 Clifton Rd, MS D-14
Atlanta, GA 30333

Dear Dr. Frieden:

This letter is in response to your request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of the Centers for Disease Control and Prevention’s (CDC) Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA) for the presumptive detection of Zika virus-specific IgM in human sera or cerebrospinal fluid (CSF) that is submitted alongside a patient-matched serum specimen from individuals meeting CDC Zika virus clinical criteria (e.g., a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g., recent history of travel to geographic regions during a period of active Zika virus transmissions at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated as part of a public health response), by qualified laboratories designated by CDC and, in the United States, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests, pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. § 360bbb-3). Where there are positive or equivocal results from the Zika MAC-ELISA, confirmation of the presence of anti-Zika IgM antibodies requires additional testing by CDC, or by authorized laboratories in consultation with CDC, using the CDC-issued algorithm.

On February 26, 2016, pursuant to section 564(b)(1)(C) of the Act (21 U.S.C. § 360bbb-3(b)(1)(C)), the Secretary of Health and Human Services (HHS) determined that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves Zika virus. Pursuant to section 564(b)(1) of the Act (21 U.S.C. § 360bbb-3(b)(1)), and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection

1 For ease of reference, this letter will refer to "qualified laboratories designated by CDC and, in the United States, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests" as "authorized laboratories."

2 As amended by the Pandemic and All Hazards Preparedness Reauthorization Act, Pub. L. No. 113-5, under section 564(b)(1)(C) of the Act, the Secretary may make a determination of a public health emergency, or of a significant potential for a public health emergency.
I. Criteria for Issuance of Authorization

I have concluded that the emergency use of the Zika MAC-ELISA for the presumptive detection of Zika virus-specific IgM antibodies in the specified population meets the criteria for issuance of an authorization under section 564(c) of the Act, because I have concluded that:

1. The Zika virus can cause Zika virus infection, a serious or life-threatening disease or condition to humans infected with the virus;

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that the Zika MAC-ELISA may be effective in diagnosing Zika virus infection when positive or equivocal results are further tested by CDC or by authorized laboratories in consultation with CDC, using the CDC-issued algorithm, and that the known and potential benefits of the Zika MAC-ELISA for diagnosing Zika virus infection outweigh the known and potential risks of such product when positive or equivocal results are further tested by CDC or by authorized laboratories in consultation with CDC, using the CDC-issued algorithm; and

3. There is no adequate, approved, and available alternative to the emergency use of the Zika MAC-ELISA for diagnosing Zika virus infection.\(^4\)

II. Scope of Authorization

I have concluded, pursuant to section 564(d)(1) of the Act, that the scope of this authorization is limited to the use of the authorized Zika MAC-ELISA by authorized laboratories for the

---


\(^4\) No other criteria of issuance have been prescribed by regulation under section 564(c)(4) of the Act.
The Authorized Zika MAC-ELISA

The Zika MAC-ELISA is an IgM antibody capture enzyme-linked immunosorbent assay for the in vitro qualitative detection of Zika virus-specific IgM antibodies in human sera and other authorized specimen types from individuals meeting CDC Zika virus clinical criteria (e.g., a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g., recent history of travel to geographic regions during a period of active Zika virus transmissions at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated as part of a public health response) by authorized laboratories where positive or equivocal results are further tested by CDC or by authorized laboratories in consultation with CDC, using the CDC-issued algorithm.

The test procedure is based on capturing human IgM antibodies from the patient specimen on a microtiter plate using antihuman-IgM antibody followed by the addition of Zika virus specific antigen and detector conjugate.

One of the limitations of this test is the possibility of false positive results in patients with a history of infection with other flaviviruses. Additional testing of equivocal and positive specimens as specified in the CDC-issued algorithm is therefore required to confirm the presence of IgM antibodies to Zika virus.

The assay uses a purified antibody specific for human IgM that is immobilized on a test plate to capture IgM antibodies from a human specimen. A serum or CSF specimen from a patient is added to the test plate, and IgM antibodies from the specimen bind to the immobilized antibody. After washing, cultured Zika virus antigen is added and binds to any Zika virus-specific IgM antibodies captured on the plate. A flavivirus specific monoclonal antibody conjugated to horseradish peroxidase is then added. Upon addition of substrate, conjugate that is bound to any immobilized Zika antigen will catalyze a colorimetric reaction that can be measured by a spectrophotometer.

The Zika MAC-ELISA includes the following materials:

- Lyophilized Normal Vero E6 Antigen (CDC catalog #AV0001)
- Lyophilized Zika Vero E6 Tissue Culture Antigen (CDC catalog #AV002 or AV003) consisting of Zika antigen prepared specifically for use in the Zika MAC-ELISA
- Lyophilized Flavivirus IgM Positive Control (CDC catalog #AV004), a chimeric monoclonal antibody specific for flaviviruses
The Zika MAC-ELISA requires the following control materials:

- Positive Control:
  
  * **Flavivirus IgM Positive Control:** This product is a flavivirus group reactive humanized IgM antibody used to establish the Positive Control P/N ratio, which validates the plate run. This control is included in the Zika MAC-ELISA.

- Negative Controls:
  
  * **Normal Vero E6 Antigen:** This control is used to measure the background signal generated by each specimen. This control is included in the Zika MAC-ELISA.

  * **Negative control serum:** The negative control serum (tested negative for Zika virus) is non-reactive with viral antigen and is used to establish the Specimen P/N ratio, which also validates the plate run. This control is not included in the Zika MAC-ELISA.

Controls listed above must be included on each 96-well plate. Controls must generate expected results in order for a plate to be considered valid.

The Zika MAC-ELISA also requires the use of the following additional materials as described in the Instructions for Use:

- 96-well plate
- Detecting antibody conjugate: Horseradish peroxidase conjugated monoclonal antibody 6B6C-1, specific for human IgM
- Goat anti-human IgM
- Negative control serum
- Enhanced K-Blue TMB substrate (3,3', 5, 5' tetramethylbenzidine base)

The above described Zika MAC-ELISA, when labeled consistently with the labeling authorized by FDA entitled “Zika MAC-ELISA Instructions for Use” (available at http://www.fda.gov/MedicalDevices%20Safety/EmergencySituations/ucm161496.htm), which may be revised by CDC in consultation with FDA, is authorized to be distributed to and used by authorized laboratories under this EUA, despite the fact that it does not meet certain requirements otherwise required by federal law.

The above described Zika MAC-ELISA is authorized to be accompanied by the following information pertaining to the emergency use, which is authorized to be made available to health care providers, pregnant women, and other patients:

- Fact Sheet for Health Care Providers: Interpreting Zika MAC-ELISA Results
Page 5 – Dr. Frieden, Centers for Disease Control and Prevention

- Fact Sheet for Pregnant Women: Understanding Results from the Zika MAC-ELISA
- Fact Sheet for Patients: Understanding Results from the Zika MAC-ELISA

As described in Section IV below, CDC is also authorized to make available additional information relating to the emergency use of the authorized Zika MAC-ELISA that is consistent with, and does not exceed, the terms of this letter of authorization.

I have concluded, pursuant to section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of the authorized Zika MAC-ELISA in the specified population, when used for presumptive detection of Zika virus-specific IgM antibodies and used consistently with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of such a product.

I have concluded, pursuant to section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that the authorized Zika MAC-ELISA may be effective in the diagnosis of Zika virus infection, when used consistently with the Scope of Authorization of this letter (Section II), pursuant to section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that the authorized Zika MAC-ELISA, when used to diagnose Zika virus infection in the specified population (as described in the Scope of Authorization of this letter (Section II)), meets the criteria set forth in section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of the authorized Zika MAC-ELISA under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination described above and the Secretary of HHS's corresponding declaration under section 564(b)(1), the Zika MAC-ELISA described above is authorized to diagnose Zika virus infection in individuals meeting CDC Zika virus clinical criteria (e.g., a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g., recent history of travel to geographic regions during a period of active Zika virus transmissions at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated as part of a public health response).

This EUA will cease to be effective when the HHS declaration that circumstances exist to justify the EUA is terminated under section 564(b)(2) of the Act or when the EUA is revoked under section 564(g) of the Act.

III. Waiver of Certain Requirements

I am waiving the following requirements for the Zika MAC-ELISA during the duration of this EUA:
• Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of the Zika MAC-ELISA.

• Labeling requirements for cleared, approved, or investigational devices, including labeling requirements under 21 CFR 809.10 and 21 CFR 809.30, except for the intended use statement (21 CFR 809.10(a)(2), (b)(2)), adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)), any appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4), and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).

IV. Conditions of Authorization

Pursuant to section 564 of the Act, I am establishing the following conditions on this authorization:

Centers for Disease Control and Prevention (CDC)

A. CDC will distribute the authorized Zika MAC-ELISA with the authorized labeling, as may be revised by CDC in consultation with FDA, only to authorized laboratories.\(^5\)

B. CDC will provide to authorized laboratories the authorized Zika MAC-ELISA Fact Sheet for Health Care Providers, the authorized Zika MAC-ELISA Fact Sheet for Pregnant Women, and the authorized Zika MAC-ELISA Fact Sheet for Patients.

C. CDC will make available on its website the authorized Zika MAC-ELISA Fact Sheet for Health Care Providers, the authorized Zika MAC-ELISA Fact Sheet for Pregnant Women, and the authorized Zika MAC-ELISA Fact Sheet for Patients.

D. CDC will inform authorized laboratories and relevant public health authority(ies) of this EUA, including the terms and conditions herein.

E. CDC will ensure that authorized laboratories using the authorized Zika MAC-ELISA have a process in place for reporting test results to health care providers and relevant public health authorities, as appropriate.

F. CDC will track adverse events and report to FDA under 21 CFR Part 803.

\(^5\) Current stocks of CDC Zika MAC-ELISA products previously distributed to authorized laboratories and labeled as “Research Use Only (RUO)” may be used by such laboratories for research use and/or diagnostic purposes under this authorization in accordance with the authorized Instructions for Use for the CDC Zika MAC-ELISA. Such stocks used for diagnostic purposes must be used in accordance with the conditions of this authorization.
G. Through a process of inventory control, CDC will maintain records of device usage.

H. CDC will collect information on the performance of the assay. CDC will report to FDA any suspected occurrence of false negative results and significant deviations from the established performance characteristics of the assay of which CDC becomes aware.

I. CDC is authorized to make available additional information relating to the emergency use of the authorized Zika MAC-ELISA that is consistent with, and does not exceed, the terms of this letter of authorization.

J. CDC may request changes to the authorized Zika MAC-ELISA Fact Sheet for Health Care Providers, the authorized Zika MAC-ELISA Fact Sheet for Pregnant Women, and the authorized Zika MAC-ELISA Fact Sheet for Patients. Such requests will be made by CDC in consultation with FDA.

K. CDC may request the addition of other specimen types for use with the authorized Zika MAC-ELISA. Such requests will be made by CDC in consultation with, and require concurrence of FDA.

L. CDC may request change of the CDC-issued algorithm used for confirmatory testing of Zika MAC-ELISA equivocal and presumptive positive results. Such requests will be made by CDC in consultation with, and require concurrence of FDA.

M. CDC may request the change of the Zika Vero E6 Tissue Culture Antigen that is used in the detection process of the human anti-Zika IgM in the specimen. Such request will be made by CDC in consultation with, and require concurrence of FDA.

Authorized Laboratories

N. Authorized laboratories will include with reports of the results of the Zika MAC-ELISA, the authorized Fact Sheet for Health Care Providers, the authorized Fact Sheet for Pregnant Women, and the authorized Fact Sheet for Patients. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.

O. Within the United States and its territories, authorized laboratories will report all equivocal and presumptive positive results to CDC.

P. Authorized laboratories will have a process in place to assure that positive or equivocal results are further tested by CDC or by authorized laboratories in consultation with CDC, in accordance with the CDC-issued algorithm.

Q. Authorized laboratories will have a process in place for reporting test results to health care providers and relevant public health authorities, as appropriate.

R. Authorized laboratories will collect information on the performance of the assay and
report to CDC any suspected occurrence of false positive or false negative results of which they become aware.

S. All laboratory personnel using the assay should be appropriately trained in performing and interpreting immunoassays techniques and use appropriate laboratory and personal protective equipment when handling this kit.

CDC and Authorized Laboratories

T. CDC and authorized laboratories will ensure that any records associated with this EUA are maintained until notified by FDA. Such records will be made available to FDA for inspection upon request.

Conditions Related to Advertising and Promotion

U. All advertising and promotional descriptive printed matter relating to the use of the authorized Zika MAC-ELISA shall be consistent with the Fact Sheets and authorized labeling, as well as the terms set forth in this EUA and the applicable requirements set forth in the Act and FDA regulations.

V. All advertising and promotional descriptive printed matter relating to the use of the authorized Zika MAC-ELISA shall clearly and conspicuously state that:

- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the diagnosis of Zika virus infection and not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

No advertising or promotional descriptive printed matter relating to the use of the authorized Zika MAC-ELISA may represent or suggest that this test is safe or effective for the diagnosis of Zika virus infection.

The emergency use of the authorized Zika MAC-ELISA as described in this letter of authorization must comply with the conditions and all other terms of this authorization.
V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection is terminated under section 564(b)(2) of the Act or the EUA is revoked under section 564(g) of the Act.

Sincerely,

Robert M. Califf, M.D.
Commissioner of Food and Drugs

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Statement of Organization, Functions and Delegations of Authority

This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Operations (RB), Office of Information Technology (RB5). Specifically, this notice: (1) Updates the functional statement for the Office of the Director (RB5); and (2) updates the functional statement for the Division of Enterprise Solutions and Applications Management (RB56) within the Office of Information Technology (RB5).

Office of the Director and Chief Information Officer (RB5)

The Office of Information Technology is responsible for the organization, management, and administrative functions necessary to carry out responsibilities including: (1) Architects, deploys, and supports IT infrastructure; (2) provides IT end user support; (3) develops enterprise and custom applications; (4) provides investment control, budget formulation and execution, policy development, strategic and tactical planning, and performance monitoring; (5) provides leadership in the development, review, and implementation of policies and procedures to promote improved information technology (IT) management capabilities and best practices throughout HRSA; (6) coordinates IT workforce issues and works closely with the Office of Administrative Services on IT recruitment and training issues; and (7) oversees HRSA security operations and management program.

The Office of the Director is also responsible for the IT business function including: (1) Provides oversight and management of IT budget formulation and execution; (2) serves as the focal point to OIT’s contracts; (3) provides centralized procurement services for the Office of Information Technology; and (4) serves as the coordinator for OIT’s Inter-agency and Service Level Agreements.

Chief Information Security Officer

The Chief Information Security Officer, reporting to the Chief Information Officer, provides leadership and facilitates collaboration with Agency staff to oversee the implementation of security and privacy policy in the management of their IT systems, and plans all activities associated with the Federal Information Security Management Act or other Agency security and privacy initiatives including: (1) Implements, coordinates, and administers security and privacy programs to protect the information resources of HRSA in compliance with legislation, Executive Orders, directives of the Office of Management and Budget, or other mandated requirements; (2) executes the Agency’s Risk Management Program, and evaluates and assists with the implementation of safeguards to protect major information systems and IT infrastructure; and (3) manages the development, implementation, and evaluation of HRSA’s information technology security and privacy training programs to meet requirements mandated by the Office of Management and Budget.

Division of Enterprise Solutions and Applications Management (RB56)

The Division of Enterprise Solutions and Applications Management (DESAM) develops the HRSA grants